The DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.
Bisphosphonates and other bone agents for breast cancer
Open accessAbstract
BACKGROUND: Bone is the most common site of metastatic disease associated with breast cancer (BC). Bisphosphonates inhibit osteoclast-mediated bone resorption, and novel targeted therapies such as denosumab inhibit other key bone metabolism pathways. We have studied these agents in both early breast cancer and advanced breast cancer settings. This is an update of the review originally published in 2002 and subsequently updated in 2005 and 2012. OBJECTIVES: To assess the effects of bisphosphonates and other bone agents in addition to anti-cancer treatment: (i) in women with early breast cancer (EBC); (ii) in women with advanced breast cancer without bone metastases (ABC); and (iii) in women with metastatic breast cancer and bone metastases (BCBM). SEARCH METHODS: In this review update, we searched Cochrane Breast Cancer's Specialised Register, CENTRAL, MEDLINE, Embase, the World Health Organization's International Clinical Trials Registry Platform (WHO ICTRP) and ClinicalTrials.gov on 19 September 2016. SELECTION CRITERIA: We included randomised controlled trials (RCTs) comparing: (a) one treatment with a bisphosphonate/bone-acting agent with the same treatment without a bisphosphonate/bone-acting agent; (b) treatment with one bisphosphonate versus treatment with a different bisphosphonate; (c) treatment with a bisphosphonate versus another bone-acting agent of a different mechanism of action (e.g. denosumab); and (d) immediate treatment with a bisphosphonate/bone-acting agent versus delayed treatment of the same bisphosphonate/bone-acting agent. DATA COLLECTION AND ANALYSIS: Two review authors independently extracted data, and assessed risk of bias and quality of the evidence. The primary outcome measure was bone metastases for EBC and ABC, and a skeletal-related event (SRE) for BCBM. We derived risk ratios (RRs) for dichotomous outcomes and the meta-analyses used random-effects models. Secondary outcomes included overall survival and disease-free survival for EBC; we derived hazard ratios (HRs) for these time-to-event outcomes where possible. We collected toxicity and quality-of-life information. GRADE was used to assess the quality of evidence for the most important outcomes in each treatment setting. MAIN RESULTS: We included 44 RCTs involving 37,302 women.In women with EBC, bisphosphonates were associated with a reduced risk of bone metastases compared to placebo/no bisphosphonate (RR 0.86, 95% confidence interval (CI) 0.75 to 0.99; P = 0.03, 11 studies; 15,005 women; moderate-quality evidence with no significant heterogeneity). Bisphosphonates provided an overall survival benefit with time-to-event data (HR 0.91, 95% CI 0.83 to 0.99; P = 0.04; 9 studies; 13,949 women; high-quality evidence with evidence of heterogeneity). Subgroup analysis by menopausal status showed a survival benefit from bisphosphonates in postmenopausal women (HR 0.77, 95% CI 0.66 to 0.90; P = 0.001; 4 studies; 6048 women; high-quality evidence with no evidence of heterogeneity) but no survival benefit for premenopausal women (HR 1.03, 95% CI 0.86 to 1.22; P = 0.78; 2 studies; 3501 women; high-quality evidence with no heterogeneity). There was evidence of no effect of bisphosphonates on disease-free survival (HR 0.94, 95% 0.87 to 1.02; P = 0.13; 7 studies; 12,578 women; high-quality evidence with significant heterogeneity present) however subgroup analyses showed a disease-free survival benefit from bisphosphonates in postmenopausal women only (HR 0.82, 95% CI 0.74 to 0.91; P < 0.001; 7 studies; 8314 women; high-quality evidence with no heterogeneity). Bisphosphonates did not significantly reduce the incidence of fractures when compared to placebo/no bisphosphonates (RR 0.77, 95% CI 0.54 to 1.08, P = 0.13, 6 studies, 7602 women; moderate-quality evidence due to wide confidence intervals). We await mature overall survival and disease-free survival results for denosumab trials.In women with ABC without clinically evident bone metastases, there was no evidence of an effect of bisphosphonates on bone metastases (RR 0.96, 95% CI 0.65 to 1.43; P = 0.86; 3 studies; 330 women; moderate-quality evidence with no heterogeneity) or overall survival (RR 0.89, 95% CI 0.73 to 1.09; P = 0.28; 3 studies; 330 women; high-quality evidence with no heterogeneity) compared to placebo/no bisphosphonates however the confidence intervals were wide. One study reported a trend towards an extended period of time without a SRE with bisphosphonate compared to placebo (low-quality evidence). One study reported quality of life and there was no apparent difference in scores between bisphosphonate and placebo (moderate-quality evidence).In women with BCBM, bisphosphonates reduced the SRE risk by 14% (RR 0.86, 95% CI 0.78 to 0.95; P = 0.003; 9 studies; 2810 women; high-quality evidence with evidence of heterogeneity) compared with placebo/no bisphosphonates. This benefit persisted when administering either intravenous or oral bisphosphonates versus placebo. Bisphosp
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group (2010) · BMJ · doi:10.1136/bmj.c332 · Cited by 9,329
Practical methods for incorporating summary time-to-event data into meta-analysis.
Tierney, J. F., Stewart, L. A., Ghersi, D., Burdett, S., & Sydes, M. R. (2007) · Trials · doi:10.1186/1745-6215-8-16 · Cited by 6,208
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
(2008) · Cited by 3,790
Chapter 9: Analysing Data and Undertaking Meta-Analyses
Deeks, J. J., Higgins, J. P. T., & Altman, D. G. (2008) · Cited by 2,782
Roodman, G. D. (2004) · New England Journal of Medicine · doi:10.1056/nejmra030831 · Cited by 2,755
Stewart, B. W., & Kleihues, P. (2003) · Cited by 2,386
Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases
Ruggiero, S. L., Mehrotra, B., Rosenberg, T. J., & Engroff, S. L. (2004) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2004.02.004 · Cited by 2,057
Fizazi, K., Carducci, M., Smith, M., Damião, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62344-6 · Cited by 1,971
Stopeck, A. T., Lipton, A., Body, J.-J., Steger, G. G., Tonkin, K., de Boer, R. H., Lichinitser, M., Fujiwara, Y., Yardley, D. A., Viniegra, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.7101 · Cited by 1,597
Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws
Woo, S.-B., Hellstein, J. W., & Kalmar, J. R. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-10-200605160-00009 · Cited by 1,252
Published by John Wiley & Sons Ltd
Modarresi, O. A. F., & Shakibaie, M. M. M. R. (2015) · Cited by 1,111
The clinical course of bone metastases from breast cancer
Coleman, R., & Rubens, R. (1987) · British Journal of Cancer · doi:10.1038/bjc.1987.13 · Cited by 1,084
Hortobagyi, G. N., Theriault, R. L., Porter, L., Blayney, D., Lipton, A., Sinoff, C., Wheeler, H., Simeone, J. F., Seaman, J., Knight, R. D., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612123352401 · Cited by 1,026
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
Gnant, M., Mlineritsch, B., Schippinger, W., Luschin-Ebengreuth, G., Pöstlberger, S., Menzel, C., Jakesz, R., Seifert, M., Hubalek, M., Bjelic-Radisic, V., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806285 · Cited by 1,025
Chapter 10: Addressing reporting biases
Egger, M., & Moher, D. (2011) · Cited by 997
Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A. R., Mackey, J. R., Apffelstaedt, J., Hussein, M., Coleman, R. E., Reitsma, D. J., et al. (2001) · PubMed · Cited by 896
Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A., Mackey, J., Apffelstaedt, J., Hussein, M. A., Coleman, R. E., Reitsma, D. J., et al. (2003) · Cancer · doi:10.1002/cncr.11701 · Cited by 873
Bisphosphonates: from the laboratory to the clinic and back again
Russell, R. G. G., & Rogers, M. J. (1999) · Bone · doi:10.1016/s8756-3282(99)00116-7 · Cited by 840
Reduction in New Metastases in Breast Cancer with Adjuvant Clodronate Treatment
Diel, I. J., Solomayer, E.-F., Costa, S. D., Gollan, C., Goerner, R., Wallwiener, D., Kaufmann, M., & Bastert, G. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808063390601 · Cited by 809
Lipton, A., Theriault, R. L., Hortobagyi, G. N., Simeone, J., Knight, R. D., Mellars, K., Reitsma, D. J., Heffernan, M., & Seaman, J. J. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000301)88:5<1082::aid-cncr20>3.0.co;2-z · Cited by 665
Hortobagyi, G. N., Theriault, R. L., Lipton, A., Porter, L., Blayney, D., Sinoff, C., Wheeler, H., Simeone, J. F., Seaman, J. J., Knight, R. D., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2038 · Cited by 631
Theriault, R. L., Lipton, A., Hortobagyi, G. N., Leff, R., Glück, S., Stewart, J. F., Costello, S., Kennedy, I., Simeone, J., Seaman, J. J., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.846 · Cited by 604
Bone health in cancer patients: ESMO Clinical Practice Guidelines
Coleman, R., Body, J. J., Aapro, M., Hadji, P., & Herrstedt, J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu103 · Cited by 564
Gnant, M., Pfeiler, G., Dubsky, P. C., Hubalek, M., Greil, R., Jakesz, R., Wette, V., Balic, M., Haslbauer, F., Melbinger, E., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60995-3 · Cited by 559
Paterson, A. H., Powles, T. J., Kanis, J. A., McCloskey, E., Hanson, J., & Ashley, S. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.1.59 · Cited by 557
Kohno, N., Aogi, K., Minami, H., Nakamura, S., Asaga, T., Iino, Y., Watanabe, T., Goessl, C., Ohashi, Y., & Takashima, S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.116 · Cited by 546
Fizazi, K., Lipton, A., Mariette, X., Body, J.-J., Rahim, Y., Gralow, J. R., Gao, G., Wu, L., Sohn, W., & Jun, S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.2146 · Cited by 533
Coleman, R. E., Major, P., Lipton, A., Brown, J. E., Lee, K.-A., Smith, M., Saad, F., Zheng, M., Hei, Y. J., Seaman, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.091 · Cited by 533
Gnant, M., Mlineritsch, B., Stoeger, H., Luschin-Ebengreuth, G., Heck, D., Menzel, C., Jakesz, R., Seifert, M., Hubalek, M., Pristauz, G., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70122-x · Cited by 472
A systematic review of the role of bisphosphonates in metastatic disease
Ross, J., Saunders, Y., Edmonds, P., Patel, S., Wonderling, D., Normand, C., & Broadley, K. (2004) · Health Technology Assessment · doi:10.3310/hta8040 · Cited by 467
Aapro, M., Abrahamsson, P. A., Body, J. J., Coleman, R. E., Colomer, R., Costa, L., Crinò, L., Dirix, L., Gnant, M., Gralow, J., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm442 · Cited by 457
Mundy, G. R. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971015)80:8+<1546::aid-cncr4>3.0.co;2-i · Cited by 440
Breast-Cancer Adjuvant Therapy with Zoledronic Acid
Coleman, R. E., Marshall, H., Cameron, D., Dodwell, D., Burkinshaw, R., Keane, M., Gil, M., Houston, S. J., Grieve, R. J., Barrett-Lee, P. J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105195 · Cited by 424
Body, J.-J., Diel, I. J., Lichinitser, M. R., Kreuser, E. D., Dornoff, W., Gorbunova, V. A., Budde, M., & Bergström, B. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg367 · Cited by 413
Breast-cancer Adjuvant Therapy With Zoledronic Acid
Coleman, R. E., Marshall, H. C., Cameron, D., et al. (2011) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) · Cited by 413
Lipton, A., Steger, G. G., Figueroa, J., Alvarado, C., Solal-Celigny, P., Body, J.-J., de Boer, R., Berardi, R., Gascon, P., Tonkin, K. S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8604 · Cited by 389
Randomized, Placebo-Controlled Trial of Clodronate in Patients With Primary Operable Breast Cancer
Powles, T., Paterson, S., Kanis, J. A., McCloskey, E., Ashley, S., Tidy, A., Rosenqvist, K., Smith, I., Ottestad, L., Legault, S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.080 · Cited by 377
Bisphosphonates for breast cancer
Pavlakis, N., & Stockler, M. (2002) · The Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003474 · Cited by 360
Self-citationCurrent use of bisphosphonates in oncology. International Bone and Cancer Study Group.
Body, J. J., Bartl, R., Burckhardt, P., Delmas, P. D., Diel, I. J., Fleisch, H., Kanis, J. A., Kyle, R. A., Mundy, G. R., Paterson, A. H., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3890 · Cited by 359
Van Poznak, C. H., Temin, S., Yee, G. C., Janjan, N. A., Barlow, W. E., Biermann, J. S., Bosserman, L. D., Geoghegan, C., Hillner, B. E., Theriault, R. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.5209 · Cited by 342
Saarto, T., Blomqvist, C., Virkkunen, P., & Elomaa, I. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.1.10 · Cited by 341
Coleman, R., de Boer, R., Eidtmann, H., Llombart, A., Davidson, N., Neven, P., von Minckwitz, G., Sleeboom, H. P., Forbes, J., Barrios, C., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mds277 · Cited by 339
Breast Cancer Metastasis to Bone: Mechanisms of Osteolysis and Implications for Therapy
Kozlow, W., & Guise, T. A. (2005) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-005-5399-8 · Cited by 337
Body, J. J., Diel, I. J., Lichinitzer, M., Lazarev, A., Pecherstorfer, M., Bell, R., Tripathy, D., & Bergstrom, B. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601663 · Cited by 336
Rosen, L. S., Gordon, D. H., Dugan, W., Major, P., Eisenberg, P. D., Provencher, L., Kaminski, M., Simeone, J., Seaman, J., Chen, B., et al. (2004) · Cancer · doi:10.1002/cncr.11892 · Cited by 335
Brufsky, A., Harker, W. G., Beck, J. T., Carroll, R., Tan-Chiu, E., Seidler, C., Hohneker, J., Lacerna, L., Petrone, S., & Perez, E. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3744 · Cited by 321
Gnant, M., Mlineritsch, B., Stoeger, H., Luschin-Ebengreuth, G., Knauer, M., Moik, M., Jakesz, R., Seifert, M., Taucher, S., Bjelic-Radisic, V., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu544 · Cited by 312
Coleman, R., Cameron, D., Dodwell, D., Bell, R., Wilson, C., Rathbone, E., Keane, M., Gil, M., Burkinshaw, R., Grieve, R., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70302-x · Cited by 300
Rogers, M. J., Watts, D. J., & Russell, R. G. G. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971015)80:8+<1652::aid-cncr15>3.0.co;2-z · Cited by 285
Eidtmann, H., de Boer, R., Bundred, N., Llombart-Cussac, A., Davidson, N., Neven, P., von Minckwitz, G., Miller, J., Schenk, N., & Coleman, R. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq217 · Cited by 281
Delmas, P. D., Balena, R., Confravreux, E., Hardouin, C., Hardy, P., & Bremond, A. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.955 · Cited by 278
Conte, P. F., Latreille, J., Mauriac, L., Calabresi, F., Santos, R., Campos, D., Bonneterre, J., Francini, G., & Ford, J. M. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.9.2552 · Cited by 268
Bisphosphonates for breast cancer
Pavlakis, N., Schmidt, R. L., & Stockler, M. R. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003474.pub2 · Cited by 244
Self-citationZoledronic Acid Inhibits Visceral Metastases in the 4T1/luc Mouse Breast Cancer Model
Hiraga, T., Williams, P. J., Ueda, A., Tamura, D., & Yoneda, T. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0325 · Cited by 242
Bisphosphonates and other bone agents for breast cancer
Wong, M. H., Stockler, M. R., & Pavlakis, N. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003474.pub3 · Cited by 230
Self-citationClodronate decreases the frequency of skeletal metastases in women with breast cancer
Kanis, J. A., Powles, T., Paterson, A. H. G., McCloskey, E. V., & Ashley, S. (1996) · Bone · doi:10.1016/s8756-3282(96)00285-2 · Cited by 224
Prevention of Aromatase Inhibitor–Induced Bone Loss Using Risedronate: The SABRE Trial
Van Poznak, C., Hannon, R. A., Mackey, J. R., Campone, M., Apffelstaedt, J. P., Clack, G., Barlow, D., Makris, A., & Eastell, R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.5902 · Cited by 224
Dhesy-Thind, S., Fletcher, G. G., Blanchette, P. S., Clemons, M. J., Dillmon, M. S., Frank, E. S., Gandhi, S., Gupta, R., Mates, M., Moy, B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.7257 · Cited by 222
Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer
Stockler, M., Wilcken, N. R. C., Ghersi, D., & Simes, R. J. (2000) · Cancer Treatment Reviews · doi:10.1053/ctrv.1999.0161 · Cited by 218
Self-citationBrufsky, A. M., Bosserman, L. D., Caradonna, R. R., Haley, B. B., Jones, C. M., Moore, H. C. F., Jin, L., Warsi, G. M., Ericson, S. G., & Perez, E. A. (2009) · Clinical Breast Cancer · doi:10.3816/cbc.2009.n.015 · Cited by 214
Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases.
Elomaa, I., Blomqvist, C., Gröhn, P., Porkka, L., Kairento, A.-L., Selander, K., Lamberg-Allardt, C., & Holmström, T. (1983) · The Lancet · doi:10.1016/s0140-6736(83)92755-1 · Cited by 209
Amadori, D., Aglietta, M., Alessi, B., Gianni, L., Ibrahim, T., Farina, G., Gaion, F., Bertoldo, F., Santini, D., Rondena, R., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70174-8 · Cited by 203
van Holten-Verzantvoort, A. T., Bijvoet, O. L. M., Hermans, J., Harinck, H. I. J., Elte, J. W. F., Beex, L. V. A. M., Cleton, F. J., Kroon, H. M., Vermey, P., Neijt, J. P., et al. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92555-4 · Cited by 202
Palliative pamidronate treatment in patients with bone metastases from breast cancer.
van Holten-Verzantvoort, A. T., Kroon, H. M., Bijvoet, O. L., Cleton, F. J., Beex, L. V., Blijham, G., Hermans, J., Neijt, J. P., Papapoulos, S. E., & Sleeboom, H. P. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.491 · Cited by 196
Paterson, A. H., Anderson, S. J., Lembersky, B. C., Fehrenbacher, L., Falkson, C. I., King, K. M., Weir, L. M., Brufsky, A. M., Dakhil, S., Lad, T., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70226-7 · Cited by 194
Brufsky, A. M., Harker, W. G., Beck, J. T., Bosserman, L., Vogel, C., Seidler, C., Jin, L., Warsi, G., Argonza‐Aviles, E., Hohneker, J., et al. (2012) · Cancer · doi:10.1002/cncr.26313 · Cited by 192
Body, J.-J., Diel, I. J., Bell, R., Pecherstorfer, M., Lichinitser, M. R., Lazarev, A. F., Tripathy, D., & Bergström, B. (2004) · Pain · doi:10.1016/j.pain.2004.07.011 · Cited by 190
Lester, J. E., Dodwell, D., Purohit, O. P., Gutcher, S. A., Ellis, S. P., Thorpe, R., Horsman, J. M., Brown, J. E., Hannon, R. A., & Coleman, R. E. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5101 · Cited by 189
Oral clodronate in breast cancer patients with bone metastases: a randomized study
Kristensen, B., Ejlertsen, B., Groenvold, M., Hein, S., Loft, H., & Mouridsen, H. T. (1999) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1999.00507.x · Cited by 176
Brufsky, A., Bundred, N., Coleman, R., Lambert-Falls, R., Mena, R., Hadji, P., Jin, L., Schenk, N., Ericson, S., & Perez, E. A. (2008) · The Oncologist · doi:10.1634/theoncologist.2007-0206 · Cited by 175
Diel, I. J., Body, J.-J., Lichinitser, M. R., Kreuser, E. D., Dornoff, W., Gorbunova, V. A., Budde, M., & Bergström, B. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.03.025 · Cited by 166
Lipton, A., Steger, G. G., Figueroa, J., Alvarado, C., Solal-Celigny, P., Body, J. J., de Boer, R., Berardi, R., Gascon, P., Tonkin, K. S., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5234 · Cited by 162
Cleeland, C. S., Body, J., Stopeck, A., von Moos, R., Fallowfield, L., Mathias, S. D., Patrick, D. L., Clemons, M., Tonkin, K., Masuda, N., et al. (2013) · Cancer · doi:10.1002/cncr.27789 · Cited by 159
Michiels, S., Piedbois, P., Burdett, S., Syz, N., Stewart, L., & Pignon, J.-P. (2005) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462305050154 · Cited by 154
Hershman, D. L., McMahon, D. J., Crew, K. D., Cremers, S., Irani, D., Cucchiara, G., Brafman, L., & Shane, E. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.4707 · Cited by 153
Martín, M., Bell, R. H., Bourgeois, H. P., Brufsky, A., Diel, I., Eniu, A. E., Fallowfield, L. J., Fujiwara, Y., Jassem, J., Paterson, A. H. G., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3310 · Cited by 149
Vehmanen, L., Saarto, T. H., Elomaa, I., Mäkelä, P. M., Välimäki, M. J., & BLOMQVIST, C. P. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00317-3 · Cited by 141
Changes in the epigenetic status of the SOX-9 promoter in human osteoarthritic cartilage
Kim, K., Park, Y.-S., & Im, G. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1843 · Cited by 138
Llombart‐Cussac, A., Frassoldati, A., Paija, O., Sleeboom, H. P., Jérusalem, G., Mebis, J., Deleu, I., Miller, J. C., Schenk, N., & Neven, P. (2011) · Clinical Breast Cancer · doi:10.1016/j.clbc.2011.08.002 · Cited by 136
Mechanisms of osteolytic bone destruction
Mundy, G. R. (1991) · Bone · doi:10.1016/8756-3282(91)90057-p · Cited by 131
Barrett-Lee, P. J., Casbard, A. C., Abraham, J., Hood, K., Coleman, R. E., Simmonds, P., Timmins, H., Wheatley, D. A., Grieve, R., Griffiths, G. O., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70539-4 · Cited by 128
Bloomfield, D. J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.3.1218 · Cited by 127
Coleman, R. E., Woodward, E., Brown, J. E., Cameron, D., Bell, R., Dodwell, D. J., Keane, M., Gil, M., Davies, C., Burkinshaw, R., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1429-y · Cited by 120
Weinfurt, K. P., Castel, L. D., Li, Y., Timbie, J. W., Glendenning, G. A., & Schulman, K. A. (2004) · Medical Care · doi:10.1097/01.mlr.0000108746.69256.45 · Cited by 117
Hultborn, R., Gundersen, S., Rydén, S., Holmberg, E. C., Carstensen, J. M., Wallgren, U.-B., Killany, S., Andreassen, L., Carlsson, G. U., Fahl, N., et al. (1999) · PubMed · Cited by 115
von Moos, R., Body, J.-J., Egerdie, B., Stopeck, A., Brown, J. E., Fallowfield, L. J., Patrick, D. L., Cleeland, C. S., Damyanov, D., Palazzo, F. G., et al. (2015) · Supportive Care in Cancer · doi:10.1007/s00520-015-2908-1 · Cited by 114
Bone and cancer: Pathophysiology and treatment of metastases
Kanis, J. А. (1995) · Bone · doi:10.1016/8756-3282(95)00194-i · Cited by 108
von Minckwitz, G., Möbus, V. J., Schneeweiß, A., Huober, J., Thomssen, C., Untch, M., Jackisch, C., Diel, I., Elling, D., Conrad, B., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.2167 · Cited by 104
Ellis, G. K., Bone, H. G., Chlebowski, R. T., Paul, D., Spadafora, S., Fan, M., & Kim, D. S. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0352-y · Cited by 101
METHODS FOR THE EARLY RECOGNITION OF COR PULMONALE
JONES, E. S., Scarrow, G. D., Sechiari, G., & Roberts, D. V. (1964) · The Lancet · doi:10.1016/s0140-6736(64)92229-9 · Cited by 101
Fuleihan, G. E., Salamoun, M., Mourad, Y. A., Chehal, A. A., Salem, Z. M. K., Mahfoud, Z. R., & Shamseddine, A. I. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1444 · Cited by 99
Bone metastases and breast cancer
Coleman, R. E., & Rubens, R. D. (1985) · Cancer Treatment Reviews · doi:10.1016/0305-7372(85)90008-8 · Cited by 97
Greenspan, S. L., Brufsky, A., Lembersky, B. C., Bhattacharya, R. K., Vujevich, K. T., Perera, S., Sereika, S. M., & Vogel, V. G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2967 · Cited by 94
Mauri, D., Valachis, A., Polyzos, I. P., Polyzos, N. P., Kamposioras, K. V., & Pesce, L. L. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0432-z · Cited by 92
van Holten-Verzantvoort, A. T. M., Zwinderman, A. H., Aaronson, N. K., Hermans, J., van Emmerik, B., van Dam, F. S. A. M., van den Bos, B., Bijvoet, O. L. M., & Cleton, F. J. (1991) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(91)90212-v · Cited by 92
Hines, S. L., Mincey, B. A., Dentchev, T., Sloan, J. A., Perez, E. A., Johnson, D. B., Schaefer, P., Alberts, S. R., Liu, H., Kahanic, S. P., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0332-2 · Cited by 91
Targeting the Insulin-like Growth Factor Axis for the Development of Novel Therapeutics in Oncology
Gao, J., Chang, Y. S., Jallal, B., & Viner, J. L. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-0550 · Cited by 87
Hines, S. L., Mincey, B. A., Sloan, J. A., Thomas, S. P., Chottiner, E. G., Loprinzi, C. L., Carlson, M. D., Atherton, P. J., Salim, M., & Perez, E. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.1783 · Cited by 86
Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton
Siris, E. S., Hyman, G. A., & Canfield, R. E. (1983) · The American Journal of Medicine · doi:10.1016/0002-9343(83)90958-0 · Cited by 73
Šestak, I., Singh, S., Cuzick, J. M., Blake, G. M., Patel, R., Gossiel, F., Coleman, R. E., Dowsett, M., Forbes, J., Howell, A., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71035-6 · Cited by 71
Kristensen, B., Ejlertsen, B., Mouridsen, H. T., Jensen, M., ANDERSEN, J. E., Jensen, B. B., Cold, S., Edlund, P., Ewertz, M., Kamby, C., et al. (2008) · Acta Oncologica · doi:10.1080/02841860801964988 · Cited by 70
Coleman, R. E., Bundred, N. J., Boer, R. D., Llombarto, A., Campbell, I. D., Neven, P., Barrios, C. H., Dias, R., Miller, J. C., & Brufsky, A. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-09-4082 · Cited by 65
Rathbone, E. J., Brown, J. E., Marshall, H. C., Collinson, M., Liversedge, V., Murden, G., Cameron, D., Bell, R. H., Spensley, S., Agrawal, R. K., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.4792 · Cited by 60
Hershman, D. L., McMahon, D. J., Crew, K. D., Shao, T. H., Cremers, S., Brafman, L., Awad, D., & Shane, E. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1366 · Cited by 57
Diel, I., Body, J., Stopeck, A., Vadhan‐Raj, S., Spencer, A. G., Steger, G. G., von Moos, R., Goldwasser, F., Feng, A., & Braun, A. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.04.017 · Cited by 56
Body, J. J., Lichinitser, M., Tjulandin, S. A., Garnero, P., & Bergstrom, B. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm119 · Cited by 52
Extended Safety Profile of Oral Clodronate After Long-Term Use in Primary Breast Cancer Patients
Atula, S., Powles, T. J., Paterson, A. H. G., McCloskey, E. V., Nevalainen, J., & Kanis, J. А. (2003) · Drug Safety · doi:10.2165/00002018-200326090-00005 · Cited by 52
Optimal management of bone metastases in breast cancer patients
Wong, M., & Pavlakis (2011) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s6655 · Cited by 50
Self-citationClodronate for osteolytic metastases due to breast cancer.
Elomaa, I., BLOMQVIST, C. P., Porkka, L., Holmström, T., Taube, T., Lamberg-Allardt, C. J. E., & Borgström, G. H. (1988) · PubMed · Cited by 48
Xeroderma pigmentosum.Showing common skin cancers plus melanocarcinoma controlled by surgery
Moore, C., & Iverson, P. C. (1954) · Cancer · Cited by 47
Kalder, M., Kyvernitakis, I., Albert, U. ‐., Baier-Ebert, M., & Hadji, P. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2955-3 · Cited by 45
Charehbili, A., Hamdy, N. A. T., Smit, V. T. H. B. M., Kessels, L. W., van Bochove, A., van Laarhoven, H. W. M., Putter, H., Kranenbarg, E. M., van Leeuwen‐Stok, A. E., van der Hoeven, J. J. M., et al. (2015) · The Breast · doi:10.1016/j.breast.2015.10.005 · Cited by 43
Kim, J. E., Ahn, J., Jung, K. H., Kim, S., Kim, H. J., Lee, K.-S., Ro, J., Park, Y., Ahn, J.-S., Im, Y.-H., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1201-8 · Cited by 42
McCloskey, E. V., Paterson, A. H. G., Kanis, J. А., Tähtelä, R., & Powles, T. J. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.12.003 · Cited by 38
Charehbili, A., van de Ven, S., Smit, V. T. H. B. M., Kranenbarg, E. M., Hamdy, N. A. T., Putter, H., Heijns, J. B., van Warmerdam, L. J. C., Kessels, L. W., Dercksen, M. W., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu102 · Cited by 38
Vehmanen, L., Saarto, T. H., Risteli, J., Risteli, L., BLOMQVIST, C. P., & Elomaa, I. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000041624.00665.4e · Cited by 37
Dekker, T. J. A., Charehbili, A., Smit, V. T. H. B. M., ten Dijke, P., Meershoek-Klein Kranenbarg, E., van de Velde, C. J. H., Nortier, J. W. R., Tollenaar, R. A. E. M., Mesker, W. E., & Kroep, J. R. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.02.001 · Cited by 36
Hatziieremia, S., McCall, P., Willder, J. M., Orange, C., Seywright, M. M., Underwood, M. A., & Edwards, J. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-1 · Cited by 36
Hortobágyi, G. N., Lipton, A., Chew, H. K., Gradishar, W. J., Sauter, N. P., Mohanlal, R. W., Zheng, M., McGrain, B., & Poznak, C. H. V. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.18_suppl.lba9500 · Cited by 36
von Minckwitz, G., Rezai, M., Tesch, H., Huober, J., Gerber, B., Zahm, D.-M., Hilfrich, J., Costa, S. D., Dubsky, P. C., Blohmer, J., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.05.015 · Cited by 32
Nuzzo, F., Gallo, C., Lastoria, S., Maïo, M. D., Piccirillo, M. C., Gravina, A., Landi, G., Rossi, E., Pacilio, C., Labonia, V., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr600 · Cited by 30
Fasching, P. A., Jud, S. M., Hauschild, M., Kümmel, S., Schütte, M., Warm, M., Hanf, V., Grab, D., Krocker, J., Stickeler, E., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-66 · Cited by 25
Addison, C., Bouganim, N., Hilton, J. F., Vandermeer, L., Dent, S. F., Amir, E., Hopkins, S. P., Kuchuk, I., SEGAL, R. J., Song, X., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2906-x · Cited by 25
Abstract 1: Role of the splicing factor SF2/ASF in mammary epithelial cell transformation
Anczuków, O., Rosenberg, A. Z., Muthuswamy, S. K., & Krainer, A. R. (2010) · Cancer Research · doi:10.1158/1538-7445.am10-1 · Cited by 23
Nelson, A., Fenlon, D., Morris, J., Sampson, C., Harrop, E., Murray, N., Wheatley, D. A., Hood, K., Griffiths, G. O., & Barrett-Lee, P. J. (2013) · Trials · doi:10.1186/1745-6215-14-325 · Cited by 22
Cleton, F. J., van Holten-Verzantvoort, A. T., & Bijvoet, O. L. M. (1989) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-83668-8_7 · Cited by 20
Randomized Trial of Adjuvant Zoledronic Acid in Postmenopausal Women With High-Risk Breast Cancer
Leal, T., Tevaarwerk, A. J., Love, R. R., Stewart, J. A., Binkley, N., Eickhoff, J. C., Parrot, B., & Mulkerin, D. L. (2010) · Clinical Breast Cancer · doi:10.3816/cbc.2010.n.062 · Cited by 18
Reshat, R., Priestley, C. C., & Gooderham, N. J. (2010) · Cancer Research · doi:10.1158/1538-7445.am10-6 · Cited by 15
Stopeck, A., Martín, M., Ritchie, D., Body, J. J., Paterson, A. H. G., Viniegra, M., Jassem, J., Takano, T., Poznak, C. H. V., Bourgeois, H. P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.sabcs10-p6-14-01 · Cited by 15
Suarez, T., Fizazi, K., Rahim, Y., Wilson, J., Fan, M., Jun, S., & Lipton, A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.8562 · Cited by 11
Dekker, T. J. A., Charehbili, A., Smit, V. T. H. B. M., Wasser, M., Heijns, J., van Warmerdam, L. J., Kessels, L. W., Dercksen, W., Pepels, M. J. A. E., Maartense, E., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.sabcs13-p1-06-04 · Cited by 1
Dekker, T. J. A., Charehbili, A., Smit, V. T. H. B. M., Wasser, M. N. J. M., Heijns, J. B., Warmerdam, L. J. V., Kessels, L., Dercksen, W., Pepels, M., Maartense, E., et al. (2013) · Leiden Repository (Leiden University) · Cited by 1
Berenson (2001) · doi:10.1002/1097-0142(20010401)91:7<1191::aid-cncr1119>3.0.co;2-0
Cited by
Ruggiero, S. L., Dodson, T. B., Aghaloo, T., Carlson, E. R., Ward, B. B., & Kademani, D. (2022) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2022.02.008 · Cited by 1,141
Ganesh, K., & Massagué, J. (2021) · Nature Medicine · doi:10.1038/s41591-020-01195-4 · Cited by 1,051
1st International consensus guidelines for advanced breast cancer (ABC 1)
Cardoso, F., Costa, A., Norton, L., Cameron, D., Cufer, T., Fallowfield, L., Francis, P., Gligorov, J., Kyriakides, S., Lin, N., et al. (2012) · The Breast · doi:10.1016/j.breast.2012.03.003 · Cited by 303
Biganzoli, L., Battisti, N. M. L., Wildiers, H., McCartney, A., Colloca, G., Kunkler, I. H., Cardoso, M.-J., Cheung, K.-L., de Glas, N. A., Trimboli, R. M., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30741-5 · Cited by 298
RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives
Infante, M., Fabi, A., Cognetti, F., Gorini, S., Caprio, M., & Fabbri, A. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-1001-2 · Cited by 180
“To date, adjuvant bisphosphonate treatment in breast cancer has been found to reduce disease recurrence and improve disease-free survival and overall survival only in postmenopausal settings [157, 161].”
Background
Metadata
- Authors
- O'Carrigan, B., Wong, M. H., Willson, M. L., Stockler, M. R., Pavlakis, N., & Goodwin, A.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2017-10-30
- Volume
- 2018
- Issue
- 11
- Pages
- CD003474-CD003474
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1533900546
- Cited by
- 356
- References
- 141
- FWCI
- 11.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.